Defining Progression in Metastatic Kidney Cancer
3 Ansichten
• 06/26/23
0
0
Einbetten
administrator
Abonnenten
Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.
Zeig mehr
Facebook Kommentare
SORT BY-
Beste Kommentare
-
Neueste Kommentare